Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapyAjay K Gopal, John M Pagel, Joseph G Rajendran, et al.
International Journal of Hematologic Oncology|November 29, 2021
A Phase I trial of talazoparib in patients with advanced hematologic malignanciesAjay K Gopal, Rakesh Popat, Ryan J Mattison, et al.
Cancer|July 16, 2008
High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experienceAjay K Gopal, Tracee L Metcalfe, Ted A Gooley, et al.
British Journal of Clinical Pharmacology|April 27, 2016
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairmentBaiteng Zhao, Robert Chen, Owen A O'Connor, et al.
Leukemia & Lymphoma|May 3, 2008
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaBrian G Till, Theodore A Gooley, Nathan Crawford, et al.
Cancer Research|June 19, 2007
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomasJohn M Pagel, Anastasia Pantelias, Nathan Hedin, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 10, 2018
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell LymphomaStephen D Smith, Shruti Gandhy, Ajay K Gopal, et al.
Transplantation and Cellular Therapy|May 20, 2024
Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive ChemomobilizationAndrew J Portuguese, Albert C Yeh, Rahul Banerjee, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|November 28, 2017
Long-term results of a sirolimus-eluting stent with biodegradable polymer (RAPSTROM™) in de novo coronary stenosesFilippo Figini, Cholenahaly N Manjunath, Budanur C Srinivas, et al.
British Journal of Haematology|August 23, 2014
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patientsJohn M Pagel, Stephen E Spurgeon, John C Byrd, et al.
Pageof 19